Addition of venetoclax at time of progression in ibrutinib‐treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare

To the Editor: The outcomes of patients with chronic lymphocytic leukemia (CLL) have dramatically improved with the introduction of novel agents. Final analysis of the phase III RESONATE trial reported a median progression free survival (PFS) of 44 months in relapsed/refractory CLL patients treated with ibrutinib.1 Venetoclax is effective in CLL following progression on ibrutinib, with an overall response rate (ORR) of 65% and estimated 12-month...